Download PDF
Thromb Haemost 2023; 123(04): 427-437
DOI: 10.1055/s-0042-1760365
Stroke, Systemic or Venous Thromboembolism

Bleeding Risk in Elderly Patients with Venous Thromboembolism Who Would Have Been Excluded from Anticoagulation Trials

Carla Schenker 
1   Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Odile Stalder
2   CTU Bern, University of Bern, Bern, Switzerland
,
Marie Méan
3   Division of Internal Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
,
Tobias Tritschler
1   Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Marc Righini
4   Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
,
Nicolas Rodondi
1   Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
5   Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
,
Drahomir Aujesky
1   Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
› Author Affiliations Funding The SWITCO65+ is entirely funded by grants from the Swiss National Science Foundation (grant no. 33CSCO-122659/139470). CanVECTOR Network; the Network receives grant funding from the Canadian Institutes of Health Research (CDT-142654).
› Further Information
    Permissions and Reprints


Abstract

Older patients with venous thromboembolism (VTE) are underrepresented in clinical anticoagulation trials. We examined to which extent elderly patients with VTE would be excluded from such trials and compared the bleeding risk between hypothetically excluded and enrolled patients. We studied 991 patients aged ≥65 years with acute VTE in a prospective multicenter cohort. We identified 12 landmark VTE oral anticoagulation trials from the eighth and updated ninth American College of Chest Physician Guidelines. For each trial, we abstracted the exclusion criteria and calculated the proportion of our study patients who would have been excluded from trial participation. We examined the association between five common exclusion criteria (hemodynamic instability, high bleeding risk, comorbidity, co-medication, and invasive treatments) and major bleeding (MB) within 36 months using competing risk regression, adjusting for age, sex, and periods of anticoagulation. A median of 31% (range: 20–52%) of our patients would have been excluded from participation in the landmark trials. Hemodynamic instability (sub-hazard ratio [SHR]: 2.2, 95% CI: 1.1–4.7), comorbidity (SHR: 1.5, 95% CI: 1.1–2.2), and co-medication (SHR: 1.5, 95% CI: 1.0–2.3) were associated with MB. Compared to eligible patients, those with ≥2 exclusion criteria had a twofold (SHR: 2.16, 95% CI: 1.38–3.39) increased risk of MB. Overall, about one-third of older patients would not be eligible for participation in guideline-defining VTE anticoagulation trials. The bleeding risk increases significantly with the number of exclusion criteria present. Thus, results from such trials may not be generalizable to older, multimorbid, and co-medicated patients.

Keywords

venous thromboembolism - anticoagulation - bleeding risk - exclusion criteria - elderly

Authors Contribution

Concept and design: C.S., O.S., M.M., D.A. Data acquisition: M.M., M.R., N.R., D.A. Statistical analysis: O.S. Drafting of the manuscript: C.S., D.A. Critical revision of the manuscript for important intellectual content: all authors. Final approval of the manuscript: all authors.


Supplementary Material



Publication History

Received: 02 May 2022

Accepted: 16 November 2022

Article published online:
09 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 454S-545S
    CrossrefPubMedGoogle Scholar
  • 2 Nieto JA, Solano R, Ruiz-Ribó MD. et al; Riete Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8 (06) 1216-1222
    CrossrefPubMedGoogle Scholar
  • 3 Spencer FA, Gore JM, Lessard D. et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 2008; 100 (05) 780-788
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 5 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedGoogle Scholar
  • 6 Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP. Venous thrombosis in the elderly: more questions than answers. Blood 2007; 110 (09) 3097-3101
    CrossrefPubMedGoogle Scholar
  • 7 Candeias Faria D, Bicho Augusto J, Borges Santos M. et al. Eligibility criteria for non-vitamin K antagonist anticoagulants in patients with pulmonary embolism in a real world portuguese population. Eur Heart J Acute Cardiovasc Care 2016; 5: 138-139 , Abstract P298
    PubMedGoogle Scholar
  • 8 Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111 (09) 4471-4476
    CrossrefPubMedGoogle Scholar
  • 9 Moustafa F, Pesavento R, di Micco P. et al; RIETE Investigators. Real-life use of anticoagulants in venous thromboembolism with a focus on patients with exclusion criteria for direct oral anticoagulants. Clin Pharmacol Ther 2018; 103 (04) 684-691
    CrossrefPubMedGoogle Scholar
  • 10 Méan M, Righini M, Jaeger K. et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis 2013; 36 (04) 475-483
    CrossrefPubMedGoogle Scholar
  • 11 Fiessinger JN, Huisman MV, Davidson BL. et al; THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293 (06) 681-689
    CrossrefPubMedGoogle Scholar
  • 12 Pinede L, Ninet J, Duhaut P. et al; Investigators of the “Durée Optimale du Traitement AntiVitamines K” (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103 (20) 2453-2460
    CrossrefPubMedGoogle Scholar
  • 13 Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349 (18) 1713-1721
    CrossrefPubMedGoogle Scholar
  • 14 Sudlow MF, Campbell IA, Angel JH. et al; Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340 (8824): 873-876
    CrossrefPubMedGoogle Scholar
  • 15 Kearon C, Ginsberg JS, Anderson DR. et al; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2 (05) 743-749
    CrossrefPubMedGoogle Scholar
  • 16 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74 (02) 606-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Büller HR, Davidson BL, Decousus H. et al; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349 (18) 1695-1702
    CrossrefPubMedGoogle Scholar
  • 18 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (04) 389-396
    CrossrefPubMedGoogle Scholar
  • 19 Faivre R, Neuhart Y, Kieffer Y. et al. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study [in French]. Presse Med 1988; 17 (05) 197-200
    PubMedGoogle Scholar
  • 20 Hull RD, Pineo GF, Brant RF. et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
    CrossrefPubMedGoogle Scholar
  • 21 Hull RD, Pineo GF, Brant RF. et al; LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120 (01) 72-82
    CrossrefPubMedGoogle Scholar
  • 22 Kearon C, Ginsberg JS, Julian JA. et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (08) 935-942
    CrossrefPubMedGoogle Scholar
  • 23 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 24 Lee AYY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 25 Lopaciuk S, Bielska-Falda H, Noszczyk W. et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81 (01) 26-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lopaciuk S, Meissner AJ, Filipecki S. et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68 (01) 14-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 López-Beret P, Orgaz A, Fontcuberta J. et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33 (01) 77-90
    CrossrefPubMedGoogle Scholar
  • 28 Meyer G, Brenot F, Pacouret G. et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995; 74 (06) 1432-1435
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
    CrossrefPubMedGoogle Scholar
  • 30 Prandoni P, Carnovali M, Marchiori A. Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164 (10) 1077-1083
    CrossrefPubMedGoogle Scholar
  • 31 Romera A, Cairols MA, Vila-Coll R. et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37 (03) 349-356
    CrossrefPubMedGoogle Scholar
  • 32 Simonneau G, Sors H, Charbonnier B. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337 (10) 663-669
    CrossrefPubMedGoogle Scholar
  • 33 Théry C, Simonneau G, Meyer G. et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85 (04) 1380-1389
    CrossrefPubMedGoogle Scholar
  • 34 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 35 Agnelli G, Prandoni P, Becattini C. et al; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 36 Schulman S, Granqvist S, Holmström M. et al; The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336 (06) 393-398
    CrossrefPubMedGoogle Scholar
  • 37 Agnelli G, Prandoni P, Santamaria MG. et al; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345 (03) 165-169
    CrossrefPubMedGoogle Scholar
  • 38 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334 (7595): 674
    CrossrefPubMedGoogle Scholar
  • 39 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907
    CrossrefPubMedGoogle Scholar
  • 40 Kearon C, Ginsberg JS, Kovacs MJ. et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349 (07) 631-639
    CrossrefPubMedGoogle Scholar
  • 41 Ridker PM, Goldhaber SZ, Danielson E. et al; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348 (15) 1425-1434
    CrossrefPubMedGoogle Scholar
  • 42 Schulman S, Rhedin A-S, Lindmarker P. et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332 (25) 1661-1665
    CrossrefPubMedGoogle Scholar
  • 43 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 44 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 45 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 46 Schulman S, Kearon C, Kakkar AK. et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 47 Schulman S, Kearon C, Kakkar AK. et al; RE-MEDY Trial Investigators, ; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 48 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 49 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 50 Frei AN, Stalder O, Limacher A. et al. Comparison of bleeding risk scores in elderly patients receiving extended anticoagulation with vitamin K antagonists for venous thromboembolism. Thromb Haemost 2021; 121 (11) 1512-1522
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337 (10) 657-662
    CrossrefPubMedGoogle Scholar
  • 52 Jakobsson C, Jiménez D, Gómez V, Zamarro C, Méan M, Aujesky D. Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism. J Thromb Haemost 2010; 8 (06) 1242-1247
    CrossrefPubMedGoogle Scholar
  • 53 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94 (446) 496-509
    CrossrefPubMedGoogle Scholar
  • 54 Beers E, Moerkerken DC, Leufkens HGM, Egberts TCG, Jansen PA. Participation of older people in preauthorization trials of recently approved medicines. J Am Geriatr Soc 2014; 62 (10) 1883-1890
    CrossrefPubMedGoogle Scholar
  • 55 Crome P, Cherubini A, Oristrell J. The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert Rev Clin Pharmacol 2014; 7 (04) 457-468
    CrossrefPubMedGoogle Scholar
  • 56 European Medicines Agency. Adequacy of guidance on the elderly regarding medicinal products for human use. Valid from 2006–12–14. Accessed October 7, 2021 at: https://www.ema.europa.eu/en/human-regulatory/research-development/medicines-older-people
    PubMedGoogle Scholar
  • 57 U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry. E7 studies in support of special populations: geriatrics - questions and answers. 2012 Accessed October 7, 2021 at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics-questions-and-answers
    PubMedGoogle Scholar
  • 58 Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005; 365 (9453): 82-93
    CrossrefPubMedGoogle Scholar
  • 59 Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014; 12: 21
    CrossrefPubMedGoogle Scholar